Join Conscio Group upcoming webinar on December 12 at 2:00 PM CET (expected length up to 2 hours), where industry experts will discuss the latest trends in regulation, R&D and clinical testing. In our session we will particularly explore potential regulatory changes regarding the waiver of Phase 3 efficacy studies.

Topics include:

  • Navigating Biosimilar Regulations: Evolution, Challenges, and Future Directions
  • Common pitfalls on the path from R&D to biotech product commercialization
  • Strategies for successful bioassay transfer and validation – the importance of standardization

Speakers: Elena Guillen Benitez, MD, PhD from Leiden University Medical Center, Martin Baur from Midas Pharma, and Klemens Weitenthaler from Conscio Group.

Moderator: Stephan Holl, CEO Conscio Group

Gain insider knowledge on the biosimilar industry – register here!

Additional News

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.

  • 8 června 2023

    Clinical Tips – Drug Interactions in Advanced Clinical Trial Design

    Drug interactions play a key role in the design of clinical trials. Learn how we investigate such interactions when conducting pharmacokinetic/bioequivalence studies and while offering end-to-end support throughout the process.

ALL POSTS